ClinicalTrials.gg
TerminatedNCT06870487Updated May 8, 2026

A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers

A Phase 1 interventional study of PF-08046032 and Sasanlimab in Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma and Classical Hodgkin Lymphoma, sponsored by Pfizer. Terminated at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Why this study was terminated
The trial was terminated for strategic business reasons; the decision was not based on any safety and/or efficacy concerns

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 164 studies in Lymphoma, T-Cell, Peripheral with a site in United States — 21 open to participants now, 28 under way, 2 of them phase 3. Lymphoma, T-Cell, Peripheral · United States.

Enrollment
136th of 157
6 · median 36
Started
2025
with 4 others
Phase 1
65 of 164
8 open now
Registered
156th of 164
by date

Among the 164 studies in Lymphoma, T-Cell, Peripheral with a site in United States, this one is the 136th largest by enrollment of the 157 interventional ones that give a count, is one of 5 that started in 2025, is one of 65 in phase 1, and was the 156th registered.

Lymphoma, T-Cell, Peripheral

372 studies on the registry are indexed under Lymphoma, T-Cell, Peripheral; 110 are open to participants now.

Browse Lymphoma, T-Cell, Peripheral studies →

Open to participants now

21 of the 164 studies in Lymphoma, T-Cell, Peripheral with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 76 Lymphoma, T-Cell, Peripheral studies recruiting now, 30 (39%) set no upper age limit and 38 (50%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 164 studies in Lymphoma, T-Cell, Peripheral with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to learn about the effects of a new study medicine called PF-08046032, when taken alone and when taken with another medicine called sasanlimab, for the treatment of advanced cancers. The effects are studied in adult participants with certain types of lymphomas or solid tumors that are advanced or metastatic (spread to other parts of the body).

The study has three parts:

  • Part A will test PF-08046032 alone at increasing dose levels in participants with certain lymphomas (cancer that begins in cells of the immune system) and in participants with certain solid tumors whose disease has worsened on or after standard treatments.
  • Part B will test PF-08046032 (at selected doses) and sasanlimab in participants with certain solid tumors, including those whose disease has worsened on or after standard treatments as well as participants before receiving standard treatments.
  • Part C will further test the combination of PF-08046032 and sasanlimab in participants with specific types of solid tumors based on the results from Part A and Part B of the study.

All participants will receive the study drug PF-08046032. Only participants in Part B and Part C of the study will also receive sasanlimab. PF-08046032 will be given as an intravenous (IV) infusion, which means it will be injected directly into a vein. Sasanlimab will be given as a subcutaneous injection, which means it will be injected under the skin.

03

Conditions studied

  • Peripheral T Cell Lymphoma
  • Diffuse Large B-cell Lymphoma
  • Classical Hodgkin Lymphoma
  • Head and Neck Squamous Cell Carcinoma
  • Melanoma
  • Non-Small Cell Lung Cancer

Keywords

  • Solid tumors
  • Advanced Malignancies
  • Malignancies
  • Lung cancer
  • Skin cancer
  • Non-Hodgkin lymphoma
  • Hodgkin lymphoma
  • Advanced Cancers
  • Head and Neck Cancer
  • Metastatic Cancer
  • Blood Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Histological or cytological diagnosis of or unresectable :

    • Part A1: Participants with lymphomas (cHL, PTCL, large B-cell lymphoma) who have progressed on/after standard therapies
    • Part A2: Participants with solid tumors (NSCLC, HNSCC, melanoma, or other limited tumor types) who have progressed on or following prior if indicated and available
    • Part B: Participants with solid tumors who have either progressed on/after prior immune checkpoint inhibitor, or who have not received prior immune checkpoint inhibitor therapy
    • Part C: Participants with selected tumor type who have not received systemic anticancer treatment for the tumor type (including prior immune checkpoint inhibitor
  2. as defined by Lugano Classification for lymphomas or 1.1 for solid tumors
  3. Able to provide tumor tissue(s) as defined by the protocol depending on the Part of the study at enrollment
  4. Performance Status score 0 or 1

Exclusion criteria

EXCLUSION CRITERIA:

  1. Ongoing peripheral neuropathy
  2. History of significant immune-mediated adverse event considered related to prior immune-modulatory therapy
  3. Known or suspected active disease
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    PF-08046032 Monotherapy Dose Escalation

    PF-08046032 will be given as an intravenous (IV) infusion.

    Drug: PF-08046032

  • Experimental
    PF-08046032 + Sasanlimab Combination Safety Evaluation

    PF-08046032 will be given as an intravenous (IV) infusion and sasanlimab will be administered as a subcutaneous injection.

    Drug: PF-08046032 · Drug: Sasanlimab

  • Experimental
    PF-08046032 + Sasanlimab Combination Expansion Cohort

    PF-08046032 will be given as an intravenous (IV) infusion and sasanlimab will be administered as a subcutaneous injection.

    Drug: PF-08046032 · Drug: Sasanlimab

Interventions

  • DrugPF-08046032

    PF-08046032 will be administered intravenously (IV) infusion.

  • Sasanlimab will be administered as subcutaneous (SC) injection.

06

What researchers measure

Primary outcomes

  1. Part A and Part B: Number of participants with dose limiting toxicities (DLTs) in dose escalation

    DLT (any of the prespecified AEs that are attributable to study treatment(s), excluding toxicities clearly due to underlying disease or extraneous causes) rate estimated based on data from DLT-evaluable participants during the DLT evaluation period

    Time frame: Day of first dose (Day 1) through the end of DLT Observation period (up to 28 days)

  2. All Parts: Number of participants with adverse events (AEs)

    AEs as characterized by type, frequency, severity (CTCAE v5), seriousness, and relationship to study drug(s)

    Time frame: From first dose (Day 1) through up to 30 days after last dose of PF-08046032 or up to 90 days after last dose of sasanlimab

  3. All Parts: Frequency of dose modifications due to AEs

    Dose modifications such as dose delay, treatment interruptions, dose reducations, and treatment discontinuations due to AEs

    Time frame: From first dose (Day 1) through up to 30 days after last dose of PF-08046032 or up to 90 days after last dose of sasanlimab

  4. All Parts: Number of participants with clinically significant lab abnormalities

    Lab abnormalities characterized by type, frequency, and severity (CTCAE v5)

    Time frame: From first dose (Day 1) through up to 30 days after last dose of PF-08046032 or up to 90 days after last dose of sasanlimab

Secondary outcomes

  1. Objective Response Rate (ORR) in Participants with Solid Tumors

    Based on investigator assessment, and defined as the proportion of participants who achieved best overall response of CR or PR according to RECIST 1.1

    Time frame: Response assessments at baseline and every 8 to 12 weeks through time of disease progression, death, unacceptable toxicity, or through study completion (Approximately 3 Years)

  2. Duration of Response (DoR) in Participants with Solid Tumors

    Based on investigator assessment for participants with a confirmed objective response (CR or PR) only.

    Time frame: Time from first documented objective response to the date of first documented radiographic progression or death (Approximately 3 Years)

  3. Progression-free survival (PFS) in Participants with Solid Tumors

    Based on investigator assessment for tumor response/progression according to RECIST v1.1

    Time frame: Time from first dose (Day 1) to the date of first documented radiographic progression or death (Approximately 3 Years)

  4. Objective Response Rate (ORR) in participants with lymphomas based on Lugano Criteria

    Based on investigator assessment, and defined as the proportion of participants who achieved best overall response according to Lugano Criteria

    Time frame: Response assessments at baseline and every 8 to 12 weeks through time of disease progression, death, unacceptable toxicity, or through study completion (Approximately 3 Years)

  5. Progression-free survival (PFS) in participants with lymphomas based on Lugano Criteria

    Based on investigator assessment for tumor response/progression according to Lugano Response Classification Criteria

    Time frame: Time from first dose (Day 1) to the date of first documented radiographic progression or death (Approximately 3 Years)

  6. Duration of Response (DoR) in participants with lymphomas based on Lugano Criteria

    Based on investigator assessment for participants with a confirmed objective response only.

    Time frame: Time from first documented objective response to the date of first documented radiographic progression or death (Approximately 3 Years)

  7. Complete Response Rate (CRR) in participants with lymphomas

    Based on investigator assessment, and defined as the proportion of participants who achieved best overall response of Complete Response (CR) according to Lugano Criteria

    Time frame: Response assessments at baseline and every 8 to 12 weeks through time of disease progression, death, unacceptable toxicity, or through study completion (Approximately 3 Years)

  8. Duration of Complete Response (DCR) in participants with lymphomas

    Based on investigator assessment for participants with lymphoma with a confirmed objective response per Lugano Criteria only.

    Time frame: Time from first documented CR to the date of the first radiographic progression or death (Approximately 3 Years)

  9. Part C only: Overall survival (OS)

    OS is defined as time from first dose of study treatment to death due to any cause.

    Time frame: Baseline through date of death or study completion, whichever occurs first (up to approximately 3 Years)

  10. Part A2 only: Change from baseline of the number of CD25+ cells in tumor in response to PF-08046032 treatment

    Change is evaluated from paired biopsies

    Time frame: Baseline through about 7 weeks after first dose

  11. Pharmacokinetics (PK): Serum Area Under the Curve (AUC) from Time Zero to Last Quantifiable Concentration (AUClast)

    AUClast of PF-08046032 as a monotherapy (Part A) and in combination with sasanlimab (Part B and Part C).

    Time frame: Cycle 1 and Cycle 2, and pre-and post-dosing on Day 1 of Cycle 3, 4, 6, 8, and every 4th cycle thereafter; and within approximately 30 days after last dose of study drug (each cycle is 28 days)

  12. PK: Maximum Observed Serum Concentration (Cmax)

    Cmax of of PF-08046032 as a monotherapy (Part A) and in combination with sasanlimab (Part B and Part C).

    Time frame: Cycle 1 and Cycle 2, and pre-and post-dosing on Day 1 of Cycle 3, 4, 6, 8, and every 4th cycle thereafter; and within approximately 30 days after last dose of study drug (each cycle is 28 days)

  13. PK: Half-life (t1/2)

    Half life of PF-08046032 as a monotherapy (Part A) and in combination with sasanlimab (Part B and Part C)

    Time frame: Cycle 1 and Cycle 2, and pre-and post-dosing on Day 1 of Cycle 3, 4, 6, 8, and every 4th cycle thereafter; and within approximately 30 days after last dose of study drug (each cycle is 28 days)

  14. PK: Minimum observed serum concentration (Ctrough)

    Ctrough of PF-08046032 as a monotherapy (Part A) and in combination with sasanlimab (Part B and Part C)

    Time frame: Cycle 1 and Cycle 2, and pre-and post-dosing on Day 1 of Cycle 3, 4, 6, 8, and every 4th cycle thereafter; and within approximately 30 days after last dose of study drug (each cycle is 28 days)

  15. PK: Time to Reach Maximum Observed Serum Concentration (Tmax)

    Tmax of PF-08046032 as a monotherapy (Part A) and in combination with sasanlimab (Part B and Part C)

    Time frame: Cycle 1 and Cycle 2, and pre-and post-dosing on Day 1 of Cycle 3, 4, 6, 8, and every 4th cycle thereafter; and within approximately 30 days after last dose of study drug (each cycle is 28 days)

  16. Incidence of Anti-Drug Antibody (ADA): Immunogenicity of PF-08046032 as a single agent (Part A) and in combination with sasanlimab (Part B and Part C)

    Immunogenicity of PF-08046032 and in combination with sasanlimab

    Time frame: Pre-dose on Day 1 of Cycles 1-4, then cycle 6, 8, and every 4th cycle thereafter, and within approximately 30 days after last dose of study drug (each cycle is 28 days)

07

Study locations

4 sites
  • NEXT Oncology
    San Antonio, Texas 78229, United States
  • Fred Hutchinson Cancer Center.
    Seattle, Washington 98109, United States
  • University of Washington Medical Center- Montlake
    Seattle, Washington 98195, United States
  • Hospital Universitario Fundación Jiménez Díaz
    Madrid, 28040, Spain
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2025 to primary completion in Apr 2026, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2025
First posted
Mar 11, 2025
StartActual
May 8, 2025
Primary completionActual
Apr 23, 2026
CompletionActual
Apr 23, 2026
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06870487
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Mar 11, 2025
Start date
May 8, 2025
Primary completion
Apr 23, 2026
Completion
Apr 23, 2026
Last update
May 8, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion